Product Highlight - LAZCLUZE

Lazcluze in combination of Rybrevant is The Only Chemo Free Combination Preferred Regimen Recommended by NCCN (Category 1) in 1L cEGFRm Advanced NSCLC¹

• The median OS benefit with Rybrevant + Lazcluze was projected to over 4 years and exceed 1 year vs osimertinib (NE vs 36.7 months, HR 0.75 p=0.0005).²
• Rybrevant + Lazcluze targeting both the extracellular and intracellular catalytic EGFR domains, demonstrated a synergistic clinical benefit.³
• Rybrevant + Lazcluze reduces common resistance mechanisms (e.g., EGFR or MET) versus osimertinib, suggesting that this regimen is changing the underlying biology of EGFR-mutant disease, contributing to both first- and second-line long-term efficacy outcomes.⁴

LAZCLUZE is now available in combination with Rybrevant.

NCCN: National Comprehensive Cancer Network; cEGFRm: common epidermal growth factor receptor mutation; NSCLC: non-small cell lung cancer; OS: overall survival; MET: mesenchymal-epithelial transition

References:
1. NCCN guideline for NSCLC 2026 version 6.
2. Yang, J.C.-H., et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med 2025;393:1681-93. DOI: 10.1056/NEJMoa2503001.
3. Maione P., et al. National Library of Medicine. Cancers (Basel). 2025 Feb 28;17(5):847. https://doi.org/10.3390/cancers17050847.
4. Hayashi H., et al. Journal of Thoracic Oncology. Available online 28 April 2026, 103894. https://doi.org/10.1016/j.jtho.2026.103894.

For healthcare professionals only. Please refer to the latest approved version indicated with abbreviated PI.